MedTrace Logo

Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis

NCT06874634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-03-13

No results posted yet for this study

Summary

Hypoalbuminemia has been shown to be significantly associated with increased mortality from abdominal sepsis, and early albumin infusion to maintain high serum albumin concentrations may be beneficial for the recovery of patients with abdominal sepsis. However, there have been no reports on whether administering albumin infusion can improve the prognosis, and there is no unified standard for the optimal serum albumin level for exogenous albumin infusion. This study aims to retrospectively collect patients with abdominal sepsis from 2017 to 2022, and divide them into three groups based on their serum albumin levels on the first day of admission to the ICU (D1): high albumin group (HA): albumin level\>35g/L, medium albumin group (MA): albumin level between 30-35g/L, low albumin group (LA): albumin level\<30g/L, to explore the relationship between different albumin levels and 28 day mortality rate, as well as the corresponding time point fluid balance The effects of vasoactive drug dosage and organ function, mechanical ventilation time, AKI incidence and renal function outcomes, CRRT usage rate, and hospital stay.

Conditions

  • 28-day Mortality

Interventions

DRUG

Human serum albumin injection

Infusion of human albumin injection into patients with abdominal sepsis admitted to the ICU

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-11
Primary Completion
2025-01-30
Completion
2025-01-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06874634 on ClinicalTrials.gov